Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada; (i)Alberta Inflammatory Bowel Disease Consortium, University of Calgary, Calgary, Alberta, Canada.
Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; (i)Alberta Inflammatory Bowel Disease Consortium, University of Calgary, Calgary, Alberta, Canada.
EBioMedicine. 2017 Jul;21:188-196. doi: 10.1016/j.ebiom.2017.06.012. Epub 2017 Jun 16.
NOD2 and smoking are risk factors for Crohn's disease. We meta-analyzed NOD2-smoking interactions in Crohn's disease (Phase 1), then explored the effect of age at diagnosis on NOD2-smoking interactions (Phase 2).
Phase 1: MEDLINE and EMBASE were searched for studies (n=18) providing data on NOD2 and smoking in Crohn's disease. NOD2-smoking interactions were estimated using odds ratios (ORs) and 95% confidence intervals (CIs) calculated using random effects models. Phase 2: A case-only study compared the proportion of smokers and carriers of the 1007fs variant across ages at diagnosis (≤16, 17-40, >40years).
Phase 1: Having ever smoked was less common among carriers of the 1007fs variant of NOD2 (OR 0.74, 95%CI:0.66-0.83). There was no interaction between smoking and the G908R (OR 0.96, 95%CI:0.82-1.13) or the R702W variant (OR 0.89, 95%CI:0.76-1.05). Phase 2: The proportion of patients (n=627) carrying the 1007fs variant decreased with age at diagnosis (≤16years: 15%; 17-40: 12%; >40: 3%; p=0.003). Smoking was more common in older patients (≤16years: 4%; 17-40: 48%; >40: 71%; p<0.001).
The negative NOD2-smoking interaction in Crohn's disease is specific to the 1007fs variant. However, opposing rates of this variant and smoking across age at diagnosis may explain this negative interaction.
NOD2 和吸烟是克罗恩病的风险因素。我们对 NOD2-吸烟相互作用进行了荟萃分析(第 1 阶段),然后探索了诊断时年龄对 NOD2-吸烟相互作用的影响(第 2 阶段)。
第 1 阶段:使用 MEDLINE 和 EMBASE 搜索提供 NOD2 和吸烟在克罗恩病中数据的研究(n=18)。使用优势比(OR)和使用随机效应模型计算的 95%置信区间(CI)来估计 NOD2-吸烟相互作用。第 2 阶段:一项病例对照研究比较了诊断时年龄(≤16 岁、17-40 岁、>40 岁)的吸烟者和 NOD2 1007fs 变异携带者的比例。
第 1 阶段:NOD2 1007fs 变异携带者中曾吸烟的比例较低(OR 0.74,95%CI:0.66-0.83)。吸烟与 G908R(OR 0.96,95%CI:0.82-1.13)或 R702W 变异(OR 0.89,95%CI:0.76-1.05)之间无相互作用。第 2 阶段:携带 1007fs 变异的患者比例(n=627)随诊断时年龄而降低(≤16 岁:15%;17-40 岁:12%;>40 岁:3%;p=0.003)。吸烟在年龄较大的患者中更为常见(≤16 岁:4%;17-40 岁:48%;>40 岁:71%;p<0.001)。
克罗恩病中 NOD2-吸烟的负相互作用特定于 1007fs 变异。然而,该变异和吸烟在诊断时年龄的相反比率可能解释了这种负相互作用。